Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma
NCT06571396
·
clinicaltrials.gov ↗
RECRUITING
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Carcinoma, Hepatocellular
Immunotherapy
Sponsor
Qilu Hospital of Shandong University